A Spike on the Protein Electrophoresis: Evaluating Monoclonal Gammopathy of Undetermined Significance Found During a Workup for Back Pain in a 72-Year-Old Woman
[Student Name]
University of Phoenix
NRP/556: Adult and Geriatric Management II
Week 4 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mrs. L., a 72-year-old retired librarian, had four weeks of low back pain after lifting a suitcase. Because of her age, her previous clinician ordered laboratory tests, including a serum protein electrophoresis, which showed a monoclonal protein of 0.9 g/dL, IgG kappa. Her back pain has since improved with physical therapy. She comes to our clinic worried after reading about myeloma online. This paper explains the evaluation.
What an M-Protein Is
A monoclonal protein, or M-protein, is an immunoglobulin produced by a single clone of plasma cells. It can occur in monoclonal gammopathy of undetermined significance, a precursor condition, or in malignant plasma cell disorders such as multiple myeloma.
How Common Is This
Kyle et al. (2006) tested more than 21,000 residents of Olmsted County, Minnesota, and found MGUS in 3.2% of those aged 50 or older and 5.3% of those 70 or older. At Mrs. L.'s age, MGUS is a common finding, most often discovered incidentally, as hers was.
Excluding Myeloma
The International Myeloma Working Group defines MGUS as a serum M-protein under 3 g/dL, clonal plasma cells in the bone marrow under 10% and the absence of myeloma-defining events, including hypercalcemia, renal insufficiency, anemia and bone lesions, often remembered as CRAB (Rajkumar et al., 2014). To exclude myeloma, I order a complete blood count, calcium, creatinine, serum free light chains and a urine protein study. Because she had back pain, I also order imaging to look for bone lesions; the working group criteria include low-dose whole-body CT or similar imaging for this purpose.
Her Results
Her blood count, serum calcium and kidney function all fall within normal limits. The serum free light chain ratio is normal. Low-dose whole-body CT shows degenerative changes in the lumbar spine and no lytic lesions. She has no myeloma-defining events, and her M-protein is under 3 g/dL. With these results, a bone marrow biopsy is not required in her low-risk situation.
Her back pain came from a suitcase, not from her marrow, and the tests that proved it also set her baseline for years of watching.
The Diagnosis
Mrs. L. has IgG kappa MGUS.
Her Risk of Progression
Kyle et al. (2002) followed 1,384 patients with MGUS from southeastern Minnesota for up to 35 years. MGUS progressed to multiple myeloma or a related disorder in 115 patients, and the cumulative probability of progression was 12% at 10 years, 25% at 20 years and 30% at 25 years, about 1% per year. The initial M-protein concentration was a significant predictor of progression. Risk models also use the immunoglobulin type and the free light chain ratio. Mrs. L. has an M-protein below 1.5 g/dL, IgG type and a normal free light chain ratio, which place her in the lowest risk group.
What This Means for Her
At 72, with a low-risk profile, Mrs. L.'s chance of developing myeloma in her lifetime is small, and she is far more likely to die of something else. I explain that MGUS is not cancer, that most people with it never develop a plasma cell disorder and that the purpose of monitoring is to detect the rare change early.
Monitoring Plan
For low-risk MGUS, I will repeat serum protein electrophoresis and a complete blood count, calcium and creatinine in six months and, if stable, every two to three years or sooner if symptoms develop. I teach her the symptoms that should prompt earlier evaluation: new bone pain, especially persistent or at night, unexplained fatigue, frequent infections, numbness in the feet or foamy urine.
Why Risk Stratification Matters
Not all MGUS carries the same risk. Kyle et al. (2002) found that the initial size of the M-protein predicted progression, and later risk models added the immunoglobulin type and the free light chain ratio. People with none of the adverse features have a very low lifetime risk, while those with all three have a considerably higher one. Stratification determines how intensively to monitor and whether to involve a hematologist.
When to Refer
For low-risk MGUS, primary care can monitor without routine hematology referral. Referral would be appropriate if the M-protein rises, the free light chain ratio becomes abnormal, a new CRAB feature appears or unexplained symptoms such as neuropathy develop. I explain this plan to Mrs. L. so she understands that monitoring in primary care is a considered choice, not a lack of attention.
Talking About Uncertainty
Mrs. L. asked why doctors call it undetermined significance. I explained that the name reflects that most people with MGUS never develop a problem, but that no test can say in advance which few will. The monitoring plan is the answer to that uncertainty.
Her Worry
She had read frightening stories online. I encouraged her to bring questions to visits rather than searching late at night and gave her a printed summary of her results and the plan, which she found calming.
Associated Risks
Beyond progression, MGUS is associated with a higher risk of fractures and osteoporosis and, less commonly, of peripheral neuropathy and kidney disease. Her bone density scan from last year showed osteopenia; I ensure she takes adequate calcium and vitamin D and discuss fracture prevention.
The Back Pain
Her back pain, the reason for the original tests, has improved with physical therapy. Imaging showed only degenerative changes. I encourage her to continue the exercises and to report any new, persistent or night pain, which in someone with MGUS would prompt earlier re-evaluation.
Documentation
The note records the M-protein level and type, the free light chain ratio, the results of each test used to exclude myeloma, the risk category and the monitoring schedule with the symptoms that should trigger earlier testing. This record allows any future clinician to see her baseline and judge change.
Lifestyle and General Health
There is no diet or supplement that prevents MGUS from progressing. The best general advice is to stay active, keep vaccinations current, since some patients have reduced immune responses, and continue routine age-appropriate screening. I check that her pneumococcal and influenza vaccines are up to date.
Her Questions Answered
Mrs. L. asked whether her children should be tested. MGUS does occur more often in relatives of people with plasma cell disorders, but routine screening of family members without symptoms is not recommended, and I explained this to her. She also asked whether she could travel and garden as usual; she can, since MGUS itself causes no symptoms and requires no restrictions.
Conclusion
Mrs. L.'s IgG kappa M-protein of 0.9 g/dL, with normal blood counts, calcium, kidney function, free light chain ratio and bone imaging, meets the definition of MGUS rather than myeloma. Mayo Clinic data show MGUS is common at her age and progresses at about 1% per year, and her profile places her in the lowest risk group. A clear explanation, periodic monitoring and teaching about warning symptoms address both the small risk and her fear.
References
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J., III. (2006). Prevalence of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 354(13), 1362-1369. https://doi.org/10.1056/NEJMoa054494
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J., III. (2002). A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346(8), 564-569. https://doi.org/10.1056/NEJMoa01133202
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., . . . Miguel, J. F. S. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 15(12), e538-e548. https://doi.org/10.1016/S1470-2045(14)70442-5
How this NRP 556 Week 4 example is structured
The NRP/556 Week 4 work usually addresses hematologic and immune conditions. This paper uses a common incidental finding in older adults to show how to separate a benign condition from a malignant one, communicate a small but lifelong risk and plan monitoring. Students search this week as NRP 556 Week 4, NRP556 Wk 4 or NRP/556 Wk 4; all three are the same assignment.
NRP/556 Week 4 questions, answered
What does NRP/556 Week 4 usually ask for?
Many sections present a hematologic or immune condition, such as anemia or an abnormal protein finding, and ask for evaluation and management.
What is MGUS?
Monoclonal gammopathy of undetermined significance: a small monoclonal protein in the blood, fewer than 10% clonal plasma cells in the marrow and no organ damage from a plasma cell disorder.
How often does MGUS become myeloma?
In a long-term Mayo Clinic study, MGUS progressed to myeloma or a related disorder at about 1% per year, with a cumulative risk of 12% at 10 years and 25% at 20 years.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.